Therapeutic Drug Monitoring in IBD: Prospective Promise Unfulfilled
暂无分享,去创建一个
[1] P. Higgins,et al. Machine Learning Algorithms for Objective Remission and Clinical Outcomes with Thiopurines , 2017, Journal of Crohn's & colitis.
[2] M. Regueiro,et al. Silent Crohn's Disease Predicts Increased Bowel Damage During Multiyear Follow-up: The Consequences of Under-reporting Active Inflammation , 2016, Inflammatory bowel diseases.
[3] D. Franchimont,et al. Drug-concentration versus symptom-driven dose adaptation of Infliximab in patients with active Crohn's disease: a prospective, randomised, multicentre trial (Tailorix) , 2016 .
[4] M. Silverberg,et al. Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn's Disease. , 2016, Journal of Crohn's & colitis.
[5] J. Colombel,et al. Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management , 2016, Clinical and Translational Gastroenterology.
[6] K. Van Steen,et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. , 2015, Gastroenterology.
[7] M. Barclay,et al. Therapeutic drug monitoring in rheumatic diseases: utile or futile? , 2014, Rheumatology.
[8] S. Vermeire,et al. Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Current State and Future Perspectives , 2014, Current Gastroenterology Reports.
[9] Christopher F. Martin,et al. Randomised clinical trial: individualised vs. weight‐based dosing of azathioprine in Crohn's disease , 2014, Alimentary pharmacology & therapeutics.
[10] J. Lund,et al. Patterns of 6-mercaptopurine and azathioprine maintenance therapy among a cohort of commercially insured individuals diagnosed with Crohn’s disease in the United States , 2013, Clinical epidemiology.
[11] P. Rutgeerts,et al. Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient , 2013, The American Journal of Gastroenterology.
[12] S. Saini,et al. Cost utility of inflammation-targeted therapy for patients with ulcerative colitis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[13] F. Casellas,et al. Thiopurine methyl‐transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine‐treated inflammatory bowel disease patients , 2011, Alimentary pharmacology & therapeutics.
[14] Sijian Wang,et al. Algorithms outperform metabolite tests in predicting response of patients with inflammatory bowel disease to thiopurines. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[15] V. Armstrong,et al. 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. , 2007, Clinical chemistry.
[16] G. Fick,et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. , 1995, Annals of internal medicine.